The national lockdowns forced on the country during the COVID-19 pandemic were tough on us all, but for Vobster Quay owner Martin Stanton, they provided the perfect opportunity to ‘pay it forward’ by applying cutting-edge CCR technology to the fight against COVID-19.
While the rest of the country followed government guidance to ‘stay home, protect the NHS and save lives’, Martin applied his efforts to something that could save many lives across the globe – the development of a new class of CPAP (Continuous Positive Airway Pressure) ventilator designed to help patients with severe breathing difficulties.
Drawing upon considerable expertise gained through years of developing the acclaimed VMS RedBare CCR, Martin’s 3CPAP ventilator incorporates state-of-the-art CCR principles to deliver a simple yet highly effective solution that is more cost and resource efficient than conventional CPAP systems used in hospital ICU departments worldwide.
Originally conceived during the first wave of COVID-19 in the UK, its primary goal is to deliver adjustable CPAP with adjustable fractional inspired oxygen concentrations, using very low fresh gas flow.
What Martin has achieved that is unique – and something of a first – is to make a CCR perform CPAP. The result is a device that uses considerably less oxygen than a conventional CPAP device. An average UK general hospital can deliver around 3,000 litres of oxygen per minute shared between all patients that need it, making oxygen a premium yet limited resource.
With conventional CPAP machines consuming on average 50 litres of per minute, that caps the total number of patients that can receive CPAP treatment to a maximum of 60 – if the hospital were to exceed this limitation, the system would shut down leaving patients with no oxygen at all.
CCR technology ‘revolutionary’
Using a rebreather-based system like 3CPAP, that same hospital could treat over 1,000 patients from the same supply – equating to the treatment of 16 times more patients from a device that also costs a lot less than comparable conventional CPAP system.
Such a system has tremendous potential not only in hospitals but also in care homes and locations worldwide where the large volumes of oxygen needed to run conventional CPAP devices may not be available.
3CPAP ‘has the very real potential to allow acute CPAP to be delivered using oxygen concentrators, during transport and in countries where oxygen supplies are limited’, commented the Medical Devices Testing and Evaluation Centre.
Regulatory testing of Martin’s 3CPAP device is almost complete, with UK patient trials set to begin in August. The NHS here in the UK has already placed an order for 1,000 3CPAP machines, and Martin hopes that once the NHS order is complete, applications will begin to secure certifications required to export 3CPAP to other countries.
Photo credit: Jason Brown